Biogen Inc. Common Stock (BIIB) Financial Statements
Historical financial data — 40 statements covering FY2016–FY2025
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and con...
Biogen Inc. Common Stock's revenue increased 2.2% year over year, from $9.68B to $9.89B.
Net income decreased 20.8% over the same period, from $1.63B to $1.29B.
Over the 9-year period from FY2016 to FY2025, revenue declined by 14% in total.
Total debt decreased by 100.0% to $0.
The debt-to-equity ratio stands at 0.00, indicating a conservative leverage profile.
Operating cash flow declined 23.3% to $2.20B.
Biogen Inc. Common Stock maintains a healthy net profit margin of 13.1%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $7.45B+51.4% | $911.4M | $5.53B | $3.59B | $1.53B | $28.19B | $6.79B | $14.48B |
| Q1 FY2024 | $2.29B-69.3% | $393.4M | $1.75B | $464.8M | $553.2M | $26.57B | $6.29B | $15.21B |
| Q2 FY2024 | $4.76B+107.6% | $977.0M | $3.67B | $1.16B | $1.18B | $26.80B | $6.29B | $15.89B |
| Q3 FY2024 | $7.22B+51.9% | $1.37B | $5.49B | $1.61B | $2.11B | $28.31B | $4.55B | $16.36B |
| Q1 FY2025 | $2.43B-66.3% | $240.5M | $1.80B | $311.2M | $259.3M | $28.03B | $4.55B | $16.98B |
| Q2 FY2025 | $5.08B+108.8% | $875.3M | $3.84B | $1.06B | $420.2M | $28.33B | $6.28B | $17.63B |
| Q3 FY2025 | $7.61B+49.9% | $1.34B | $5.70B | $1.61B | $1.69B | $29.21B | $6.29B | $18.21B |
| Q1 FY2026 | $2.48B-67.4% | $319.5M | $1.82B | $377.7M | $645.5M | $29.48B | $6.29B | $18.65B |
Balance Sheet Summary (Latest Period)
Total Assets
$29.44B
Total Liabilities
$11.18B
Total Equity
$18.26B
Cash & Equivalents
$807.2M
Total Debt
$0
Current Assets
$8.97B
Current Liabilities
$3.35B
Retained Earnings
$20.55B